Axsome Therapeutics, Inc. (NASDAQ:AXSM) Stock Holdings Reduced by Dana Investment Advisors Inc.

Dana Investment Advisors Inc. lowered its position in Axsome Therapeutics, Inc. (NASDAQ:AXSM) by 6.7% during the fourth quarter, HoldingsChannel.com reports. The firm owned 16,394 shares of the company’s stock after selling 1,183 shares during the quarter. Dana Investment Advisors Inc.’s holdings in Axsome Therapeutics were worth $1,387,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently bought and sold shares of AXSM. Iron Triangle Partners LP purchased a new position in Axsome Therapeutics in the third quarter valued at about $22,671,000. Principal Financial Group Inc. boosted its stake in shares of Axsome Therapeutics by 6,002.7% during the 4th quarter. Principal Financial Group Inc. now owns 207,065 shares of the company’s stock worth $17,520,000 after acquiring an additional 203,672 shares in the last quarter. FMR LLC boosted its stake in shares of Axsome Therapeutics by 20.6% during the 3rd quarter. FMR LLC now owns 1,088,087 shares of the company’s stock worth $97,786,000 after acquiring an additional 185,951 shares in the last quarter. abrdn plc boosted its stake in shares of Axsome Therapeutics by 553.3% during the 4th quarter. abrdn plc now owns 72,179 shares of the company’s stock worth $6,107,000 after acquiring an additional 61,131 shares in the last quarter. Finally, Franklin Resources Inc. boosted its stake in shares of Axsome Therapeutics by 47.5% during the 3rd quarter. Franklin Resources Inc. now owns 160,534 shares of the company’s stock worth $13,713,000 after acquiring an additional 51,696 shares in the last quarter. Hedge funds and other institutional investors own 81.49% of the company’s stock.

Insider Buying and Selling at Axsome Therapeutics

In other Axsome Therapeutics news, CFO Nick Pizzie sold 3,000 shares of the company’s stock in a transaction that occurred on Friday, February 14th. The stock was sold at an average price of $131.07, for a total value of $393,210.00. Following the completion of the transaction, the chief financial officer now owns 42,187 shares of the company’s stock, valued at $5,529,450.09. This represents a 6.64 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Insiders own 22.40% of the company’s stock.

Axsome Therapeutics Trading Down 1.8 %

Axsome Therapeutics stock opened at $122.17 on Friday. The business has a 50 day moving average price of $108.78 and a two-hundred day moving average price of $97.76. The company has a quick ratio of 2.04, a current ratio of 2.11 and a debt-to-equity ratio of 3.22. The stock has a market cap of $5.96 billion, a price-to-earnings ratio of -20.40 and a beta of 0.99. Axsome Therapeutics, Inc. has a 12 month low of $64.11 and a 12 month high of $139.13.

Axsome Therapeutics (NASDAQ:AXSM) last posted its quarterly earnings results on Tuesday, February 18th. The company reported ($0.96) EPS for the quarter, beating the consensus estimate of ($0.97) by $0.01. The firm had revenue of $118.77 million during the quarter, compared to analysts’ expectations of $117.83 million. Axsome Therapeutics had a negative return on equity of 223.51% and a negative net margin of 74.47%. As a group, equities analysts forecast that Axsome Therapeutics, Inc. will post -2.79 EPS for the current year.

Wall Street Analysts Forecast Growth

Several research firms have recently issued reports on AXSM. Mizuho upped their price target on Axsome Therapeutics from $195.00 to $212.00 and gave the stock an “outperform” rating in a research note on Wednesday, February 26th. Needham & Company LLC reiterated a “buy” rating and set a $153.00 price target on shares of Axsome Therapeutics in a research note on Monday, March 3rd. Leerink Partners upped their price target on Axsome Therapeutics from $110.00 to $150.00 and gave the stock an “outperform” rating in a research note on Monday, February 10th. Morgan Stanley upped their price target on Axsome Therapeutics from $125.00 to $190.00 and gave the stock an “overweight” rating in a research note on Thursday, February 27th. Finally, Cantor Fitzgerald reiterated an “overweight” rating and set a $153.00 price target on shares of Axsome Therapeutics in a research note on Wednesday, February 19th. One equities research analyst has rated the stock with a hold rating and fifteen have given a buy rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $167.36.

Axsome Therapeutics Company Profile

Axsome Therapeutics, Inc, a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company’s commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea.